Covid19
Conditions
Brief summary
COVID-19 is a worldwide pandemic. Around 5% of infected patients are admitted in ICU, mainly for respiratory failure. Outcome of these patients is linked to other organ failures. Optimal therapies are not defined so far. The sponsor want to assess the role of MR-ProADM as prognostic biomarker, and the impact of treatments (including supportive treatments) on MOF occurrence and outcome.
Interventions
OTHERMR-Pro-ADM
Dosage of MR-pro-ADM
Sponsors
Centre Hospitalier de Lens
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Any adult patient admitted in the ICU with COVID-19 pneumonia
Exclusion criteria
* Pregnancy * Legal reasons (patients under guardianship, curatorship) * Patient's refusal
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation. | comparison to day 1 and day 3 | Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation. |
| mortality at day 28 and day 90. | admission until day 90 | mortality at day 28 and day 90. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Association between MR-ProADM and mortality at day 28. | admission until day 28 | Association between MR-ProADM and mortality at day 28. |
| Association or correlation between patient factor or treatment, and the onset or aggravation of visceral failures (day 3 and day 10), evolution until day 28. | admission until day 28 | Association or correlation between patient factor or treatment, and the onset or aggravation of visceral failures (day 3 and day 10), evolution until day 28. |
Countries
France
Outcome results
None listed